Full Text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The coronavirus has become the most interesting virus for scientists because of the recently emerging deadly SARS-CoV-2. This study aimed to understand the behavior of SARS-CoV-2 through the comparative genomic analysis with the closest one among the seven species of coronavirus that infect humans. The genomes of coronavirus species that infect humans were retrieved from NCBI, and then subjected to comparative genomic analysis using different bioinformatics tools. The study revealed that SARS-CoV-2 is the most similar to SARS-CoV among the coronavirus species. The core genes were shared by the two genomes, but there were some genes, found in one of them but not in both, such as ORF8, which is found in SARS-CoV-2. The ORF8 protein of SARS-CoV-2 could be considered as a good therapeutic target for stopping viral transmission, as it was predicted to be a transmembrane protein, which is responsible for interspecies transmission. This is supported by the molecular interaction of ORF8 with both the ORF7 protein, which contains a transmembrane domain that is essential to retaining the protein in the Golgi compartment, and the S protein, which facilitates the entry of the coronavirus into host cells. ORF1ab, ORF1a, ORF8, and S proteins of SARS-CoV-2 could be immunogenic and capable of evoking an immune response, which means that these four proteins could be considered a potential vaccine source. Overall, SARS-CoV-2 is most related to SARS-CoV. ORF8 could be considered a potential therapeutic target for stopping viral transmission, and ORF1ab, ORF1a, ORF8, and the S proteins of SARS-CoV-2 could be utilized as a potential vaccine source.

Details

Title
Potential Therapeutic Target and Vaccines for SARS-CoV-2
Author
Hussain, Mohamed A 1   VIAFID ORCID Logo  ; Hassan, Mohamed M 2   VIAFID ORCID Logo  ; Bashir Abdrhman Bashir 3   VIAFID ORCID Logo  ; Gamar, Tarig A 4   VIAFID ORCID Logo  ; Gasmalbari, Elmuaiz 5 ; Ahmed Osman Mohamed 1   VIAFID ORCID Logo  ; Osman, Wadah 6 ; Sherif, Asmaa E 7 ; Elgaml, Abdelaziz 8   VIAFID ORCID Logo  ; Alhaddad, Aisha A 9 ; Ghazawi, Kholoud F 10 ; Miski, Samar F 9 ; Ainousah, Bayan E 11   VIAFID ORCID Logo  ; Yusra Saleh Andijani 9   VIAFID ORCID Logo  ; Ibrahim, Sabrin R M 12   VIAFID ORCID Logo  ; Mohamed, Gamal A 13   VIAFID ORCID Logo  ; Ashour, Ahmed 7   VIAFID ORCID Logo 

 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum 11111, Sudan; [email protected] 
 Department of Hematology, Faculty of Medical Laboratory Science, National University, Khartoum 11111, Sudan; [email protected] 
 Department of Hematology, Faculty of Medical Laboratory Sciences, Port Sudan Ahlia College, Port Sudan 33312, Sudan; [email protected] 
 Department of Medical Parasitology, Faculty of Medical Laboratory Sciences, University of Sciences and Technology, Khartoum North 13311, Sudan; [email protected] 
 Faculty of Medicine, Omdurman Islamic University, Al Khartoum 14415, Sudan; [email protected] 
 Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; [email protected] (W.O.); [email protected] (A.E.S.); [email protected] (A.A.); Department of Pharmacognosy, Faculty of Pharmacy, University of Khartoum, Al-Qasr Ave, Khartoum 11111, Sudan 
 Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; [email protected] (W.O.); [email protected] (A.E.S.); [email protected] (A.A.); Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35511, Egypt 
 Microbiology and Immunology Department, Faculty of Pharmacy, Mansoura University, Mansoura 35511, Egypt; [email protected]; Microbiology and Immunology Department, Faculty of Pharmacy, Horus University, New Damietta 34517, Egypt 
 Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30078, Saudi Arabia; [email protected] (A.A.A.); [email protected] (S.F.M.); [email protected] (Y.S.A.) 
10  Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia; [email protected] 
11  Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia; [email protected] 
12  Preparatory Year Program, Department of Chemistry, Batterjee Medical College, Jeddah 21442, Saudi Arabia; [email protected]; Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt 
13  Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; [email protected] 
First page
926
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
20760817
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2843083447
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.